Swiss National Bank held its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock at the end of the first quarter. Swiss National Bank owned 0.12% of Arrowhead Pharmaceuticals worth $169,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in Arrowhead Pharmaceuticals by 3.7% in the first quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after buying an additional 11,099 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 88,933 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 18.0% in the fourth quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 17,201 shares during the last quarter. 30.13% of the stock is owned by institutional investors.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) opened at 1.84 on Thursday. The firm’s 50-day moving average price is $1.62 and its 200 day moving average price is $1.76. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $1.20 and a 52-week high of $8.22. The firm’s market cap is $137.58 million.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. On average, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post ($0.43) EPS for the current year.
Several equities analysts have recently issued reports on the company. Piper Jaffray Companies reiterated a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Jefferies Group LLC reiterated a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. Finally, ValuEngine cut Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $1.80.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.